Research Article
Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer

Mustafa Tas,1 Adem Yavuz,2 Mehmet Ak,3 and Bulent Ozcelik4

1Department of Obstetrics and Gynecology, Acıbadem Mehmet Ali Aydnlar University, Acıbadem Kayseri Hospital, Kayseri, Turkey
2Department of Obstetrics and Gynecology, Ömer Halisdemir University, Niğde, Turkey
3Department of Obstetrics and Gynecology, Kayseri City Hospital, Kayseri, Turkey
4Department of Obstetrics and Gynecology, Erciyes University, Kayseri, Turkey

Correspondence should be addressed to Mustafa Tas; drmtas@yahoo.com

Received 28 January 2019; Revised 2 July 2019; Accepted 15 July 2019; Published 29 August 2019

Academic Editor: Ozkan Kanat

Copyright © 2019 Mustafa Tas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. We aimed to determine the predictive value of several hematological markers of inflammation on the presence/absence of cervical cancer and also to determine their ability in discriminating precancerous cervical pathologies from cervical cancer. Materials and Methods. In this study, patients who presented to Acıbadem Kayseri Hospital between May 2010 and June 2018 were evaluated. Forty patients with low-grade squamous intraepithelial lesions (LSIL), 40 patients with high-grade squamous intraepithelial lesions (HSIL), and 30 patients with cervical cancer (CC) were retrospectively included in this study. A control group of 70 healthy volunteers with normal cervical cytology was also included in the study. Results. The neutrophil-to-lymphocyte ratio (NLR) was significantly higher in patients with CC than in controls. The platelet-to-lymphocyte ratio (PLR) was significantly higher in patients with CC compared to those with LSIL and HSIL diagnoses and also controls (p < 0.001). Logistic regression analysis revealed that age (OR: 1.075, 95% CI: 1.020–1.132, p = 0.007), NLR (OR: 1.643, 95% CI: 1.009–3.142, p = 0.047), and PLR (OR: 1.032, 95% CI: 1.003–1.062, p = 0.029) were predictors for the presence of CC. ROC curve analysis revealed that both NLR and PLR were predictive of CC with a cutoff value of 2.02 for NLR (71% sensitivity and 60% specificity, AUC: 0.682, p = 0.004) and 126.7 for PLR (83% sensitivity and 69% specificity, AUC: 0.752, p < 0.001). Conclusion. In addition to patients’ age, determination of NLR and PLR values, which are simple, inexpensive, and readily available markers of systemic inflammation, may help in decision making precancerous pathologies of the cervix.

1. Introduction

Globally, cervical cancer (CC) is among the three most common malignancies seen in women and leads to substantial mortality of approximately 250,000 patients each year, particularly in developing countries [1]. Novel screening methods which have been introduced in the last 20 years, such as visual inspection with acetic acid (VIA) and HPV DNA testing, have led to improvements in early detection and treatment of cervical pathologies, either as primary screening tests in combination with cytology or as adjunctive to cytology findings. Despite the advances in novel screening tests, most women in developing countries still present in the advanced stages of the disease, at a time when they are usually untreatable and only palliative measures can be taken [2]. The lack of sufficient population screening and the relatively low sensitivity of present tests necessitate the introduction of simple, inexpensive, and widely available markers as standalone tests for the screening of CC. Furthermore, tests that are capable of increasing the diagnostic accuracy of existing tests may also be critical for early diagnosis and treatment of cervical lesions.
The issue of inflammation has received considerable critical attention in not only initiation and promotion but also in the progression, invasion, and metastasis of a tumor. Recently, several surrogate markers of systemic inflammation such as serum C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been found to be associated with various kinds of cancers including non-small-cell lung cancer, pancreatic adenocarcinoma, gastric cancer, over carcinoma, renal cell carcinoma, colorectal cancers, and endometrial cancers [3–7]. Previous data have shown that precancerous pathologies of the cervix carry the potential of developing into CC. For instance, 15% of low-grade squamous intraepithelial lesions (LSILs) and 30% to 45% of high-grade squamous intraepithelial lesions (HSILs) have been reported to progress into severe disease [8]. Therefore, early recognition and discrimination of these lesions are crucial to determine patients who require aggressive treatment.

Limited data derived from previous studies suggest that both NLR and PLR are associated with unfavorable prognosis, lymph node and distant metastasis, and response to radiation therapy in patients with CC [9, 10]. However, the diagnostic ability of inflammatory markers in terms of predicting the presence/absence of precancerous cervical pathologies and CC, and the ability of these markers to discriminate precancerous cervical lesions from cancers have not been investigated yet.

The aim of the present study was to investigate several inflammation markers in terms of CC diagnosis and also their ability to discriminate patients with precancerous cervical lesions from those with CC.

2. Materials and Methods

2.1. Patient Selection. A total of 110 patients aged between 20 and 65 years and diagnosed with low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) or CC in Acıbadem Kayseri Hospital between May 2010 and June 2018 were included in this retrospective study. Data regarding the clinical features, cervical cytology, and pretreatment laboratory tests including white blood cell (WBC) count, hemoglobin, red cell distribution width, plateletcrit (PCT), platelet count, and mean platelet volume (MPV) of all patients were retrieved from hospital records. Patients were divided into three groups according to cervical cytology and histopathological examination results: LSIL, HSIL, and invasive CC (24 with squamous cell carcinoma and 6 with adenocarcinoma). The PLR was calculated by dividing absolute platelet count by absolute lymphocyte count, while the NLR was calculated by dividing absolute neutrophil count by absolute lymphocyte count. In order to eliminate the effects of confounders that might influence laboratory measurements, patients with any hematological disease, cardiovascular disease, previous malignancy, advanced liver or kidney disease, diabetes mellitus, and allergic asthma and those with active infections were not included in the study. The control group was comprised of 70 healthy volunteers with normal cervical cytology. The study was approved by the Institutional Ethical Committee of Acibadem Mehmet Ali Aydınlar University, and the study was carried out in accordance with the most recent version of the Helsinki Declaration.

2.2. Statistical Analysis. Statistical analyses were performed with SPSS software for Windows, version 20 (SPSS, Chicago, IL, USA). Continuous variables were presented as mean ± standard deviation, and categorical variables were presented as frequency (n) and percentage (%). The Kolmogorov–Smirnov test was used to determine whether or not continuous variables were normally distributed. One-way analysis of variance (ANOVA) and post hoc Tukey tests were used to compare groups. The Pearson correlation coefficient was used to examine the association between selected variables and the presence of cervix cancer. A receiver operating characteristic (ROC) curve was constructed to determine the predictive role of NLR and PLR in identifying precancerous cervical pathologies and CC. Logistic regression analysis was performed to examine the predictive value of age and laboratory measurements on the presence of CC. A multiple linear regression model was used to identify independent predictors of FIGO stage in patients with CC. A two-tailed p < 0.05 was considered significant Table 1.

3. Results

The mean age of the study group was 38 ± 10 years. Comparison of laboratory measurements of patients with LSIL, HSIL, CC, and controls is presented in Table 2. The mean age of patients with CC was higher than that of patients with LSIL and HSIL, as well as controls (46.1 ± 11 years vs. 39.4 ± 9 years, 35.8 ± 7 years, and 35.4 ± 11 years, respectively, p < 0.001). The mean hemoglobin level of patients with CC was also lower than that of patients with LSIL (12.2 ± 1.7 g/dL vs. 13.2 ± 1.2 g/dL, p = 0.033). The PCT (0.30 ± 0.1% vs. 0.24 ± 0.1%, p = 0.004) and NLR were significantly higher in patients with CC than in controls but similar to those with LSIL and HSIL. In patients with LSIL, HSIL, or CC, mean MPV was significantly higher compared to controls (9.9 ± 1.1 fl, 10.1 ± 1.0 fl, and 10.0 ± 0.8 fl vs. 8.9 ± 1.6 fl, p < 0.05 for all comparisons). The PLR was also significantly higher in patients with CC than in those with LSIL and HSIL and controls (191 ± 83 vs. 123 ± 46, 123 ± 34, and 119 ± 45, p < 0.001 for all comparisons, Figure 1).

Table 3 shows the results of the correlation analyses carried out to search the association with the presence of CC and selected parameters of complete blood count. Correlation analyses revealed that the presence of CC was significantly correlated with PLR (r = 0.452, p < 0.001) and NLR (r = 0.223, p = 0.003). Moreover, PLR was significantly correlated with the depth of stromal infiltration (r = 0.545, p = 0.007), tumor size >4 cm (r = 0.438, p = 0.037), and lymph node metastasis (r = 0.442, p = 0.035). ROC curve analysis revealed that both NLR and PLR were predictive of CC with a cutoff value of 2.02 for NLR (71% sensitivity and 60% specificity, AUC: 0.682, p = 0.004) and 126.7 for PLR.
hepatocellular carcinoma, non-small-cell lung cancer, and of PLR in various types of cancer including colorectal cancer, numerous studies have demonstrated the prognostic value of inflammation in cancer development and prognosis. A PLR, has emerged as an interesting parameter due to the role and HSIL has limited value in discriminating invasive CC from LSIL with invasive CC compared to controls. Nonetheless, PCT stage of cancer. We also found increased PCT in patients CC have higher PLR compared to patients with LSIL and HSIL. Moreover, in patients with CC, the presence of CC. However, PLR and NLR have no value in the prediction of precancerous pathologies of the cervix, including LSIL and HSIL. Moreover, in patients with CC, the NLR and the PLR are independent predictors of the FIGO stage of cancer. We also found increased PCT in patients with invasive CC compared to controls. Nonetheless, PCT has limited value in discriminating invasive CC from LSIL and HSIL.

A strong relationship between NLR and inflammation has been reported in previous studies. Increased neutrophil concentration is accepted to endorse neoplastic progression, and it can repress antineoplastic properties of lymphocytes. Accordingly, NLR may be recognized as the marker of the balance between precancerous inflammatory state and cancerous immune state, and higher NLR might be indicative for tumor development [11]. Results of previous studies suggest that NLR is strongly associated with overall survival in patients with various types of tumors, such as those originating from the lung, liver, and ovary [12–14].

Another representative index of systemic inflammation, PLR, has emerged as an interesting parameter due to the role of inflammation in cancer development and prognosis. A number of studies have demonstrated the prognostic value of PLR in various types of cancer including colorectal cancer, hepatocellular carcinoma, non-small-cell lung cancer, and ovarian cancer [15, 16]. Despite the considerable role of genetic basis in the development of malignancies, a substantial amount of recent data indicate that host immune response is also noteworthy in both the development and progression of cancer. Parameters that show the systemic inflammatory response, such as increased CRP and reduced albumin levels, have been shown to be associated with prognosis in various cancers, particularly in patients with non-small-cell lung cancer, pancreatic adenocarcinoma, gastric cancer, colorectal cancers, and renal cell carcinoma [17].

Plateletcrit (PCT) is identical to the volume that platelets have in 100 milliliters of total blood. PCT constitutes a component of the platelet indices and reflects platelet activity. Hence, high PCT indicates the higher activity of the platelets. Recent data signify that PCT acts as a surrogate marker of the systemic inflammatory response in addition to MPV, NLR, and PLR. However, the debate on the role of PLR in malignancies has not been completed yet as a consequence of the insufficient data investigating PCT in patients with cancer [18]. A short while ago Oncel and colleagues have shown that PCT was increased in patients with metastatic lung cancer compared to non-metastatic ones [19]. This relationship may partly be explained by the activity of platelets in promoting tumor growth via increasing angiogenesis. Our results for the first time show that PCT is increased in patients with CC compared to controls.

A growing body of evidence highlights the associations between the NLR or PLR and tumor characteristics in patients with CC. Increased NLR and PLR have been shown to be associated with stage, invasiveness, prognosis, and unfavorable histopathological characteristics of CC [20, 21]. Moreover, some of the studies have found that NLR and PLR are associated with LN metastasis and recurrences following chemoradiation therapy in patients with CC [22]. Our results confirm that patients with invasive CC have higher NLR and PLR compared to those with precancerous cervical pathologies. Our findings of significant correlations between PLR value and stromal infiltration depth, tumor size, and lymph node metastasis are consistent with the literature on this topic. In addition, the relationships between the NLR and PLR values and the stage of CC demonstrated in the current study are also in accordance with the findings of previous research. However, none of the studies conducted up to this point have evaluated the discriminative property of NLR and PLR in precancerous and cancerous lesions of the cervix. The present study is the first to evaluate the role of NLR and PLR in differentiating precancerous lesions from invasive CC.

The exact mechanisms underlying these results are unclear. However, there are several possible explanations for this result. Neutrophils and platelets both act in the progression and proliferation of tumor cells by influencing their vascularization. Furthermore, lymphocytes which are crucial in preventing the proliferation and metastasis of tumor cells are decreased with the advancing stages of cancer leading to higher NLRs and PLRs [23]. Our results may also reflect an ongoing immune dysfunction occurring in patients with

### Table 1: Age and hematological parameters of the study population

| Parameter                          | Value          |
|-----------------------------------|----------------|
| Age (years)                       | 38 ± 10        |
| White blood cell count (10^3/μL)  | 7.7 ± 2.3      |
| Hemoglobin (g/dL)                 | 12.7 ± 1.6     |
| Red cell distribution width (%)   | 13.7 ± 2.1     |
| Plateletcrit (%)                  | 0.26 ± 0.7     |
| Platelet count (μL)               | 273 ± 74       |
| Mean platelet volume (fl)         | 9.6 ± 1.4      |
| Neutrophil to lymphocyte ratio    | 2.2 ± 0.9      |
| Platelet to lymphocyte ratio      | 131 ± 57       |

(83% sensitivity and 69% specificity, AUC: 0.752, p < 0.001, Figure 2). However, neither NLR (AUC: 0.535, 95% CI: 0.44–0.62, p = 0.4659) nor PLR (AUC: 0.552, 95% CI: 0.45–0.64, p = 0.273) were predictive for the presence of LSIL and HSIL in ROC curve analysis. The results of logistic regression analysis showed that age (OR: 1.075, 95% CI: 1.020–1.132, p = 0.007), NLR (OR: 1.643, 95% CI: 1.099–3.142, p = 0.047), and PLR (OR: 1.032, 95% CI: 1.003–1.062, p = 0.029) were associated with CC presence (Table 4). In patients with invasive CC, linear regression analysis revealed that NLR (coefficient β = 0.315, 95% CI: 0.026–0.605, p = 0.014) and PLR (coefficient β = 0.005, 95% CI: 0.001–0.009, p = 0.014) were independently associated with the FIGO stage of cancer (Table 5).
invasive CC but not in patients with precancerous cervical pathologies. We speculate that destruction in host immune surveillance is somewhat responsible for the initiation and progression of CC. Another possible explanation for our findings is that neutrophils release several cytokines and several phagocytic mediators which are capable of inducing damage to cellular DNA, stimulate angiogenesis, and

| Table 2: Comparison of age and blood parameters in patients with LSIL, HSIL, and cervix cancer and controls. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------|----------------------|
| Patents with LSIL   | Patients with HSIL   | Patients with cancer | Controls |
|----------------------|----------------------|----------------------|----------|
| Age (years)          | 39 ± 9               | 35 ± 7               | 46 ± 11^d | 35 ± 11              | <0.001               |
| WBC count (10^3/µL)  | 7.7 ± 2.6            | 7.5 ± 1.9            | 7.3 ± 2.7 | 7.9 ± 1.8            | 0.650                |
| Hemoglobin (g/dL)    | 13.2 ± 1.2           | 12.9 ± 1.3           | 12.2 ± 1.7^b | 12.4 ± 1.7        | 0.020                |
| RDW (%)              | 13.5 ± 1.5           | 14.0 ± 1.9           | 14.4 ± 2.8 | 13.3 ± 1.9          | 0.093                |
| Plateletcrit (%)     | 0.26 ± 0.1           | 0.26 ± 0.1           | 0.29 ± 0.1^c | 0.24 ± 0.1        | 0.010                |
| Platelet count (µL)  | 263 ± 68             | 257 ± 65             | 303 ± 92^d | 274 ± 70           | 0.058                |
| MPV (fL)             | 9.9 ± 1.1            | 10.1 ± 1.0           | 10.0 ± 0.8 | 8.9 ± 1.6^a        | <0.001               |
| NLR                  | 2.2 ± 1.1            | 2.3 ± 1.0            | 2.7 ± 1.1^c | 2.0 ± 0.8         | 0.016                |
| PLR                  | 123 ± 46             | 123 ± 34             | 191 ± 83^a | 119 ± 45           | <0.001               |

HSIL: high-grade squamous intraepithelial lesion, LSIL: low-grade squamous intraepithelial lesion, MPV: mean platelet volume, NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, RDW: red cell distribution width, and WBC: white blood cell. ^a^p < 0.05 between group 3 and groups 1, 2, and 4. ^b^p < 0.05 between group 3 and group 1. ^c^p < 0.05 between group 3 and group 4. ^d^p < 0.05 between group 3 and group 2. ^e^p < 0.05 between controls and groups 1, 2, and 3.

| Table 3: Correlation of selected laboratory measurements with the presence of cervical cancer. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| r        | p        |-------------------------------------------------|-------------------------------------------------|
| Mean platelet volume  | 0.119    | 0.110                                           | Plateletcrit                                      |
| Plateletcrit         | 0.176    | 0.062                                           | Neutrophil-to-lymphocyte ratio                    |
| Neutrophil-to-lymphocyte ratio | 0.223 | 0.003                                           | Platelet-to-lymphocyte ratio                       |
| Platelet-to-lymphocyte ratio | 0.452 | <0.001                                          |

Figure 1: Graphics demonstrating neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and plateletcrit levels in patients with cervical precancerous pathologies and cervical cancer and controls.
impede apoptosis [24, 25]. Additionally, platelets release various growth factors, including platelet-derived growth factor and vascular endothelial growth factor (VEGF) which promote vascularization and proliferation of the tumors [26, 27]. Increased NLR and PLR as a result of increased neutrophil and platelet counts may contribute to the stimulation of cancer development in patients with precancerous cervical pathologies.

This study also has some limitations to be mentioned. The present study is a retrospective study and included a relatively small number of patients, especially in terms of the number of patients with invasive CC. These results, therefore, need to be interpreted with caution. In addition, the etiologies of CC cases were not recorded and analyzed; this may have masked the effects of these factors on the inflammatory characteristics of our patients. Finally, the utilization of additional markers of inflammation, such as CRP, procalcitonin, and erythrocyte sedimentation rate, may have provided additional data for the evaluation of our hypothesis; however, these markers were not measured.

In addition to patients’ age, determination of NLR and PLR values, which are simple, inexpensive, and readily available markers of systemic inflammation, may help in decision making precancerous pathologies of the cervix. Nevertheless, future studies with larger patient groups are essential to confirm the results of this preliminary study.

### Table 4: Logistic regression analysis illustrating the predictive value of age and laboratory measurements on the presence of cervical cancer.

|          | OR      | 95% CI          | p    |
|----------|---------|-----------------|------|
| Age      | 1.075   | 1.020–1.132     | 0.007|
| WBC count| 1.181   | 0.692–2.016     | 0.542|
| Plateletcrit| 3.782   | 0.223–6.749     | 0.612|
| Hemoglobin level | 0.816 | 0.613–1.085 | 0.163|
| MPV     | 1.669   | 0.983–2.831     | 0.089|
| NLR     | 1.643   | 1.009–3.142     | 0.047|
| PLR     | 1.032   | 1.003–1.062     | 0.029|

MPV: mean platelet volume; NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, and WBC: white blood cell.

### Table 5: Linear regression analysis demonstrating the association of age and laboratory parameters with FIGO stages in patients with cervical cancer.

|          | Coefficients-β | 95% CI          | p    |
|----------|----------------|-----------------|------|
| Age      | 0.005          | −0.012–0.022    | 0.536|
| WBC count| −0.028         | −0.119–0.063    | 0.530|
| Plateletcrit| −0.005         | −0.114–0.105    | 0.932|
| Hemoglobin level | 0.029 | −0.221–0.279 | 0.813|
| MPV     | 1.007          | −1.720–3.734    | 0.452|
| NLR     | 0.315          | 0.026–0.605     | 0.034|
| PLR     | 0.005          | 0.001–0.009     | 0.014|

MPV: mean platelet volume; NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, and WBC: white blood cell.

**Figure 2:** (a) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte may predict the presence of cervical cancer with a high sensitivity and specificity. (b) The sensitivity and specificity of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are extremely low in predicting cervical precancerous pathologies.

**Table 5:** Linear regression analysis demonstrating the association of age and laboratory parameters with FIGO stages in patients with cervical cancer.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] L. Wang, J. Jia, L. Lin et al., “Predictive value of hematological markers of systemic inflammation for managing cervical cancer,” *Oncotarget*, vol. 8, no. 27, p. 44824, 2017.

[2] L. Denny, “Cervical cancer: prevention and treatment,” *Discovery Medicine*, vol. 14, no. 75, pp. 125–131, 2012.

[3] G. Acmaz, H. Aksoy, D. Unal et al., “Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding?,” *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 4, pp. 1689–1692, 2014.

[4] A. T. Toriola, K. Granlevst, C. B. Aghorsangaya, A. Lukanova, M. Lehtinen, and H.-M. Surcel, “Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study,” *Annals of Oncology*, vol. 22, no. 8, pp. 1916–1921, 2011.

[5] M. Yildirim, M. Yildiz, E. Duman, S. Goktas, and V. Kaya, “Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer,” *Journal of Balkan Union of Oncology*, vol. 18, no. 3, pp. 728–732, 2013.

[6] S. Lee, S. Y. Oh, S. H. Kim et al., “Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy,” *BMC Cancer*, vol. 13, no. 1, p. 350, 2013.

[7] M. Pitchler, G. C. Hutterer, C. Stoeckig et al., “Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients,” *British Journal of Cancer*, vol. 108, no. 4, pp. 901–907, 2013.

[8] W. E. Khalbuss, D. Rudomina, N. D. Kauff, L. Chuang, and M. R. Melamed, “Spithin, a simple, inexpensive technique for preparation of thin-layer cervical cytology from liquid-based specimens,” *Cancer*, vol. 90, no. 3, pp. 135–142, 2000.

[9] Y. Zhang, L. Wang, Y. Liu et al., “Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery,” *International Journal of Gynecologic Cancer*, vol. 24, no. 7, pp. 1319–1325, 2014.

[10] M. Mizumuna, Y. Yokoyama, M. Futagami, M. Aoki, Y. Takai, and H. Mizumuna, “The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer,” *International Journal of Clinical Oncology*, vol. 20, no. 5, pp. 989–996, 2015.

[11] M. J. Proctor, D. C. McMillan, D. S. Morrison, C. D. Fletcher, P. G. Horgan, and S. J. Clarke, “A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer,” *British Journal of Cancer*, vol. 107, no. 4, pp. 695–699, 2012.

[12] K. M. Sarraf, E. Belcher, E. Raevsky, A. G. Nicholson, P. Goldstraw, and E. Lim, “Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 137, no. 2, pp. 425–428, 2009.

[13] H. Cho, H. W. Hur, S. W. Kim et al., “Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment,” *Cancer Immunology, Immunotherapy*, vol. 58, no. 1, pp. 15–23, 2009.

[14] J. Zheng, J. Cai, H. Li et al., “Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review,” *Cellular Physiology and Biochemistry*, vol. 44, no. 3, pp. 967–981, 2017.

[15] V. Asher, J. Lee, A. Innamaa, and A. Bali, “Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer,” *Clinical and Translational Oncology*, vol. 13, no. 7, pp. 499–503, 2011.

[16] H.-C. Kwon, S. H. Kim, S. Y. Oh et al., “Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer,” *Biomarkers*, vol. 17, no. 3, pp. 216–222, 2012.

[17] D. C. McMillan, “Systemic inflammation, nutritional status and survival in patients with cancer,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 12, no. 3, pp. 223–226, 2009.

[18] M. Arıcıgil, M. A. Dündar, A. Yücel, H. Arbağ, and S. K. Aziz, “Could the platelet-to-lymphocyte ratio be a novel marker for predicting invasiveness of cervical pathologies?,” *Asian Pacific Journal of Cancer Prevention*, vol. 16, no. 3, pp. 923–926, 2015.

[19] M. Zhu, M. Feng, F. He et al., “Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical cancer,” *Clinica Chimica Acta*, vol. 483, pp. 296–302, 2018.

[20] K. Nakamura, T. Nishida, T. Haruma et al., “Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy,” *Molecular and Clinical Oncology*, vol. 3, no. 5, pp. 1001–1006, 2015.

[21] P.-R. Ding, X. An, R.-X. Zhang et al., “Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIa colon cancer,” *International Journal of Colorectal Disease*, vol. 25, no. 12, pp. 1427–1433, 2010.

[22] V. C. Ardi, T. A. Kupriyanova, I. E. Deryugina, and J. P. Quigley, “Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis,” *Proceedings of the National Academy of Sciences*, vol. 104, pp. 20262–20267, 2007.

[23] E. Jablonska, W. Puzevska, Z. Grabowska, J. Jablonski, and T. Talarek, “VEGF, IL-18 and NO production by neutrophils in patients,” *International Journal of Clinical Oncology*, vol. 17, no. 3, pp. 216–222, 2012.

[24] H. Cho, H. W. Hur, S. W. Kim et al., “Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment,” *Cancer Immunology, Immunotherapy*, vol. 58, no. 1, pp. 15–23, 2009.